继7月底获得美国FDA批准之后,瑞士制药巨头诺华(Novartis)开发的抗癌药Odomzo(sonidegib,200 mg)近日再获欧盟批准,用于不适合手术治疗或放射治疗的局部晚期基底细胞癌(la BCC)成人患者的治疗。此前,Odomzo已获得澳大利亚和瑞士批准,并于今年6月25日获得欧盟CHMP建议批准的积极意见。尽管基底细胞癌很少发展为晚期,但一旦进展到这一阶段几乎没有治疗选择。Odomzo将为局部晚期BCC群体提供一 Following the approval by the U.S. FDA in late July, Odomzo (sonidegib, 200 mg), an antitumor drug developed by the Swiss pharmaceutical giant Novartis, was recently approved by the European Union for use in locally advanced basal-basal carcinoma (NSCLC) not suitable for surgery or radiation therapy la BCC) Adult patients. Earlier, Odomzo was approved by Australia and Switzerland and received positive EU approval on June 25 this year. Although basal cell carcinoma rarely progresses to advanced stage, there is almost no treatment option once it reaches this stage. Odomzo will provide one for locally advanced BCC groups